ous fistula (PCF) are known complications of head and neck surgeries, and they are the most common complications of total laryngectomy.' Patients with an OCF or PCF often complain of poor facial aesthetics, anxiety or depression, and discomfort secondary to fluid leakage. 2 ,3 A nasal septal button has been used to manage a tracheoesophageal fistula after a laryngectomy. ' We describe a novel use of a clear septal button as a temporary measure to control secretions from an OCF after total laryngectomy. The patient was a 55-year-old man with pT4N2cMx stage IV squamous cell cancer of the base of the tongue on the left side. He initially presented with dysphagia, odynophagia, occasional hemoptysis, and a 4.5-kg weight loss. His history included diabetes mellitus, hypertension, dyslipidemia, peripheral vascular occlusive disease, and morbid obesity.
In September 2012, the patient had undergone a mandible split, total glossectomy, total laryngectomy, right modified radical neck dissection from levels I through V with sacrifice of the sternocleidomastoid muscle, and selective left-sided neck dissections from levels I through IV. A left radial forearm fasciocutaneous free flap was used to reconstruct the oropharynx and tongue.
Pathology was positive for perineural invasion. The patient's condition was complicated by a dehiscence of the free flap at the left neopharynx with subsequent hemorrhage, which was controlled in the operating room on postoperative day 20. In November, he com- pleted adjuvant chemotherapy (three cycles of cisplatin) and radiotherapy (60 Gy).
In April 2013, the patient received a left pectoralis flap for closure of a left submental fistula. However, the fistula recurred at the same location, and in July he underwent correction with a right radial forearm free flap. He was next seen in September, when a leftsided 2 x 2-cm OCF was noted (figure 1). At that time, he continued packing the fistula to prevent secretions from spilling onto his skin and trachea.
The patient returned to the ENT clinic in March 2014, and a 3-cm, clear septal button (SP-78100; Summit Medical; St. Paul, Minn.) was inserted into the OCF (figure 2). A trial of water was given, and it did ---- 
INDICATIONS AND USAGE
OTiPRIO is a fluoroquinolone antibacterial indicated for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement.
DOSAGE AND ADMINISTRATION Dosage and Important Administration Instructions
• OTIPRIO isfor intratympanic administration only.
• OTIPRIO is intended for single-patient use, discard unused portion. • Administer OTIPRIO as a single intratympanic administration of one 0.1 mL (6 mg) dose into each affected ear, following suctioning of middle ear effusion.
Preparation of OTIPRIO
Directions for OTIPRIO dose preparation and handling is illustrated in Figure 1 ofthe full prescribing information.
DOSAGE FORMS AND STRENGTHS
Otic Suspension: Each 1 mL of OTIPRIO contains a white, preservative-free, sterile otic suspension consisting of 6% (60 mg/mL) ciprofloxacin in a single-patient use glass vial.
CONTRAINDICATIONS
OTIPRIO is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, orto any ofthe components of OTIPRIO.
WARNINGS AND PRECAUTIONS Potential for Microbial Overgrowth
OTIPRIO may result in overgrowth of nonsusceptible bacteria and fungi. If such infections occur, institute alternative therapy.
ADVERSE REACTIONS Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
In two randomized, sham-controlled Phase 3 clinical trials, 530 pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement were treated with OTIPRIO or sham administered intra-operatively as a single dose. The median age of the pediatric patients enrolled in the clinical trials was 1.5 years; 62% of patients were 6 months through 2 years of age and 38% of patients were greater than 2 years of age.
Adverse reactions that occurred in at least 3% of OTIPRIO patients and at an incidence greater than sham are presented inTable 1. 
Lactation

Risk Summary
Ciprofloxacin is excreted in human milk with systemic administration. However, because of the negligible systemic exposure after otic application, nursing infants of mothers receiving OTIPRIO should not be affected.
Pediatric Use
The safety and effectiveness of OTIPRIO in infants below six months of age have not been established.
The safety and effectiveness of OTIPRIO was established in approximately 530 pediatric patients with bilateral otitis media with middle ear effusion undergoing myringotomy with tympanostomy tube placement. The median age of patients enrolled in the clinical trials was 1.5 years; 62% of patients were 6 months through 2 years of age and 38% of patients were greater than 2 years of age.
For more detailed information, please read the full Prescribing Information. not spill from the wound. The patient was seen in the clinic a few more times, and he was pleased that he no longer had to pack his wound and that he was able to take small sips of thickened fluid without drainage. He also remarked that the septal button helped him regain some control of his life. He continued to undergo regular follow-up with button replacements when necessary, and he was doing well 2 years after placement. The risk factors associated with the development of an OCF or PCF include a low albumin level (a marker of malnutrition), preoperative radiation, surgery that lasts longer than 10 hours, and diabetes." Diabetics who have peripheral vascular disease are likely to also have problems with wound healing in other locations, such as the neck.
A meta-analysis by Dedivitis et al found that 35 to 50% of head and neck cancer patients are malnourished, and this also makes them prone to healing deficiencies.' The same study further noted that previous chemoradiation, which is an independent predictor of OCF and PCF development, likely exerted direct toxic effects on tissue and caused tissue hypoxia due to endarteritis obliterans and fibrosis, both of which led to poor tissue healing.
Treating an unrelenting OCF or PCF can pose many dilemmas. Both surgical and nonsurgical techniques have been attempted. Surgical interventions include sternocleidomastoid myoplasty, radial forearm free flaps, and pectoralis major flaps,"
A nonsurgical alternative is intraluminal negativepressure wound therapy. which is based on the premise that wound vacuum therapy can remove exudate from the wound bed, decrease the bacterial burden, and diminish interstitial edema." Volume 95, Number 6 Wong et al evaluated the use of a nasal septal button for preventing aspiration pneumonia from the site of a leaking tracheoesophageal prosthesis.' They noted that the use of simple procedures obviates the risks of general anesthesia, especially when patients must undergo an exhaustive procedure. The only complication they anticipated was the development of candidiasis around the prosthesis, which can be treated with antifungals. At the time Wong et al published their article, they had not replaced the septal button, and their patient was doing well 18 months after placement.
Local risk factors for OCF and PCF secondary to total laryngectomy include infections, exposure of salivary fluids, and radiation. Systemic risk factors include poor wound healing, nutritional deficiencies, diabetes, systemic sclerosis, and liver disease. Neither of these two lists is exhaustive by any means .
Using a nasal septal button as a temporizing measure to control secretions from an OCF is helpful to those patients who have previously undergone multiple procedures for closure of a fistula without avail and who do not want further surgery. The nasal septal button is easy to monitor and replace when necessary.
